anti-PSMA/anti-PSCA CAR T-cell therapy PD-1 silent (Shanghai Unicar-Therapy Bio-medicine)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameanti-PSMA/anti-PSCA CAR T-cell therapy PD-1 silent (Shanghai Unicar-Therapy Bio-medicine)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionProgrammed death-ligand 1 blockersProstate stem cell antigen modulators
TargetsProgrammed death-ligand 1Prostate stem cell antigen
Therapy Area/IndicationsHormone-Resistant Prostate Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsHormone-Resistant Prostate Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A